- 09:08 AM Mkt may be ranged around 5100 till expiry: Karvy
- 09:01 AM Rupee opens at Rs 46.29 per dollar
- 09:00 AM Nifty open interest PCR at 1.66
- 09:00 AM Liquidity will continue to fuel equity rally: LGT ...
- 08:36 AM Ganeshaspeaks: Market prediction for Nov 25
- 08:35 AM 10-year yield seen between 7.10-7.20%: RK Gurumurt...
- 08:34 AM Rupee likely to see modest gains: N Subramaniam
- 08:31 AM Fund Action witnessed in Jindal Poly Films, Ramco ...
- 08:29 AM Stocks in news: Unitech, RIL, MphasiS, Satyam, ICI...
- 08:24 AM Market cues: FIIs net sell $14.6 mn



Hyderabad based NATCO Pharma Limited has announced the launch of Pemetrexed (under the brand name of Pemnat - a 20 ml. vial injection). This is useful in the treatment of locally advanced or malignant non-small cell lung cancer.
Prescribed after prior chemotherapy, the availability of Pemnat enhances the treatment options for non-smal cell lung cancer. Also useful in the treatment of malignant pleural mesothelioma, in patients where curative surgery cannot be performed, Pemetrexed is credited with improved survival rates.
Mesothelioma is a form of cancer where malignant cells develop in the mesothelium (a protective lining that covers body's internal organs). Continuing with its stated objective of providing qualitative medicare at affordable prices, NATCO is making available Pemnat at an MRP of Rs. 25,500 per vial, as against the imported medicine costing around Rs. 79,000. Incidentally, this would be the first launch of Pemetrexed generic version in the World. Being a pre-1995 invention, NATCO does not expect any litigation over the generic launch.
Having already achieved leadership position from among the Indian companies in the oncology segment, NATCO expects to further improve its revenues with this launch.
Sourced From: NATCO Pharma Limited
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Expert sector picks to power your portfolio ahead

- Will ITC dream run continue beyond FY10?

- Mitesh Thacker's top 5 picks for trade today

- Moody's maintains negative view on India's credit condition

- Bollywood actress Shilpa Shetty marries Raj Kundra
- Den Networks closes 16% lower on first day
- Air India saves Rs 400cr through restructuring
- Worst over for India auto companies: Anand Mahindra
- Mahindra may increase car prices due to rising input costs
Source: Business Line
- Renault to continue with M&M for Logan, says Ghosn
Source: Business Line
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line










